The influence of the H-2 receptor antagonist ranitidine on cadaver kidney allograft function.
To assess the influence of ranitidine on kidney allograft function a double-blind, placebo-controlled clinical study in 42 cadaver kidney recipients has been performed. Patients received ranitidine or placebo for 1 month. Four years after transplantation 81% of the patients in the control group were alive; 67% in the control and 71% in the ranitidine group with functioning grafts. These differences were statistically not significant. However, a slightly more intensive steroid therapy was given to keep the ranitidine patients adequately immunosuppressed. Ranitidine thus can be safely used in kidney graft recipients. Because of a lack of gastrointestinal complications in both groups, no conclusions can be drawn regarding the prophylactic value of ranitidine.
D000293:Adolescent; D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000187:drug effects*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011899:Ranitidine / Q000627:therapeutic use*; D013997:Time Factors
D011899:Ranitidine